Johnson & Johnson JNJ

$275.20 +4.16 (1.53%)

Valuation

Market cap
650,648,320,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.88
Forward PE
23.73
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,991,076
Avg volume
6,956,138
Day's range
$273.60 – $278.05
Shares out
2,409,898,000
Stochastic %K
92%
Beta
0.24
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Oct 29, 7:38 PM
$SLS $JNJ $ABBV $PFE $BMY Sellas is in play right now. Institutional whales are gobbling up every loose share with their HFT trading desks before Data+ Deal. Prepare to be surprised here. 👇 ✌️🙏❤️‍🩹
0 replies
MF__DOOM Oct 29, 6:27 PM
$JNJ $PG $QQQ $SPY lol looks like I might be wrong here it’s going the complete opposite I thought
0 replies
Stocktradesmoon Oct 29, 6:24 PM
$ABCL $MRNA $SLS $LLY $JNJ 🚨UPDATE: ABcellera 🔥 🔥!!! ABCL Q3 EARNINGS AND CLINICAL CATALYSTS $ABCL has announced its participation schedule for the November investor conference. I see this announcement as more than just a notice for an institutional investor event—it’s connected to the next clinical phase of ABCL635. In particular, we need to watch whether the 12-week data we’re ve all been waiting for will be unveiled during the November 9 earnings release, or if it will lead to a separate announcement afterward. 1. 👀Upcoming Key Schedule October 22 Poster presentation on ABCL635 Phase 1/2 clinical trial at the TMS 2026 Conference November 9 Q3 2026 Earnings Release and Conference Call 7:00 AM Korea Time on November 10 November 11 Stifel Healthcare Conference November 16 Jefferies Global Healthcare Conference Q4 2026 ABCL575 Phase 1 clinical results presentation scheduled By end of 2026 Expect 12-week data for ABCL635 and updates on subsequent clinical information
0 replies
MF__DOOM Oct 29, 4:16 PM
$PG not a bad price if it gets to $150 Over due though $JNJ $SPY $QQQ
0 replies
KingTrades09 Oct 29, 2:00 PM
$IBM $JNJ $WMT If you followed me here.. you are banking.. Safe space
0 replies
Gfywoody Oct 29, 10:24 AM
$JNJ Time to drop the Sellas buyout.
0 replies
thatsolardude365 Oct 29, 8:39 AM
$JNJ: a leadership fight is still shaping the talc MDL. On May 26 the court denied Beasley Allen a stay of its disqualification in MDL 2738. Mediation continues, no global settlement, nothing to claim. Open Class Actions.
0 replies
ElliottwaveForecast Oct 29, 2:05 AM
📈 $JNJ continues to maintain a strong bullish Elliott Wave structure and remains on track to extend higher within its daily uptrend from the May 2026 low. 🚀 The current rally is expected to continue towards the 271.37 target and potentially beyond as wave ((5)) unfolds. Any short-term pullback against the 06.22.2026 low should remain supported, providing opportunities for the next leg higher within the ongoing bullish sequence. 👉 Read the full analysis: https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #JNJ #ElliottWave #Trading #Investing #TechnicalAnalysis #StockMarket #Healthcare #PriceAction #MarketOutlook #SwingTrading
0 replies